sciencedaily.com — Researchers at Fox Chase Cancer Center, in collaboration with colleagues at Memorial Sloan-Kettering Cancer Center, have shown that an engineered antibody called DTA-1 led to rejection of 50 to 60 percent of tumors in a mouse model of melanoma. The antibody allows the immune system to overcome its natural reluctance to attack tumor cells.
Apr 27, 2009 View in Crawl 4
crankmybluesaxApr 27, 2009
We don't need no stinkin' antibodies. Just get some Pentecostal idiot to pray your tumor away, cast out a few demons.
reeds1999Apr 27, 2009
Will any treatments resulting from this be placed in the public domain, or once again, will it be reserved for big pharma and the rich????